RxDoctor Payments Data

Mengyuan You, PA

Physician Assistant · Brooklyn, NYNPI 1114703477

Payments from drug & device makers

$4,113in general payments, 2019–2025

Across 152 payments — averaging $27.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$825
  • LEO Pharma Inc.$426
  • UCB, Inc.$323
  • Sun Pharmaceutical Industries Inc.$288
  • Novartis$245
  • plus $865 from 11 others

What the payments were for

  • Food & beverage$3,77292%
  • Education$3418%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,113 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$5,724
Medicare patients
26
Services billed
52

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab19$70,464
OpzeluraRuxolitinib Phosphate11$21,686
Fluocinonide136$8,472
Ammonium Lactate192$5,421
Halobetasol Propionate49$4,203
Tacrolimus15$2,957
Clotrimazole65$2,387
Clobetasol Propionate45$2,200
Ciclopirox47$2,174
Ketoconazole137$1,895
Mometasone Furoate79$1,661
Mupirocin190$1,339
Triamcinolone Acetonide100$1,008
Tretinoin12$981
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip28$549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$110$21,68611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →